Domain-specific role of IL-17RA in controlling Klebsiella pneumoniae lung infection

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R03HL154231-02

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $78,250
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Giraldina Trevejo-Nunez
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

ABSTRACT IL-17 is an essential mediator of immunity to Klebsiella pneumoniae (KP). Animal models lacking IL-17 signaling or having IL-17 receptor (IL-17R) deficiency are susceptible to KP pneumonia. Although considerable research effort has focused on how Th17 cells are generated and regulated, the mechanisms by which IL-17 and its receptor IL-17R mediate specific downstream signals in relevant disease processes such as KP pneumonia are not fully elucidated. Our efforts to understand KP pneumonia in mouse models revealed that the distal domain of IL-17RA, also known as CBAD, is indispensable to control this infection. Thus, we propose to determine the immune and molecular mechanisms by which the IL-17RA CBAD domain constrains KP pneumonia. We will also perform parallel analyses to evaluate the cell-type-specific response by single-cell RNASeq. The findings generated from this proposal will help us understand IL-17- dependent signaling mechanism by which KP pneumonia can be controlled and to evaluate the lung immune response at a single cell resolution.